Abbreviations & Acronyms AUC = area under curve HIFU = high-intensity focused ultrasound iPSA = initial prostatespecific antigen PSA = prostate-specific antigen ROC = receiver operating characteristic TURP = transurethral resection of the prostate Objectives: To identify predictive factors of biochemical recurrence for patients undergoing high-intensity focused ultrasound treatment for localized prostate cancer. Methods: We retrospectively identified patients receiving whole-gland prostate ablation with high-intensity focused ultrasound for localized prostate cancer from 2009 to 2015. All the patients received pre-high-intensity focused ultrasound radical transurethral resection of the prostate. We included perioperative parameters as follows: age, preoperative prostate volume, stage of operation, initial prostate-specific antigen, T stage, postoperative prostate-specific antigen nadir, Gleason score, time to prostatespecific antigen nadir and the presence of prostate-specific antigen biochemical recurrence. Multivariable Cox regression and Kaplan-Meier analysis were used for investigating predictors of recurrence, and receiver operating characteristic analysis was used for the cut-off values of prostate-specific antigen nadir. Results: Among 182 patients, 26.9% had prostate-specific antigen biochemical recurrence after high-intensity focused ultrasound during the median follow-up period of 32.21 months. Gleason score ≥7 (Gleason score 7, hazard ratio 2.877, P = 0.027), stage ≥T2b (T2b, hazard ratio 3.16, P = 0.027) and prostate-specific antigen nadir (hazard ratio 1.11, P < 0.001) were statistically significant, whereas there was no significance in prostate volume and initial prostate-specific antigen. We posit that a cut-off level of prostate-specific antigen nadir 0.43 ng/mL might be considered as an independent predictive factor for prostate-specific antigen biochemical recurrence in high-intensity focused ultrasound patients in multivariate analysis (P < 0.001, hazard ratio 7.39, 95% confidence interval 3.56-15.37), and created a new nadir-related prediction model for biochemical recurrence prediction. Conclusions: Postoperative prostate-specific antigen nadir of 0.43 ng/mL can be considered an important predictive factor for biochemical recurrence in primary wholeprostate gland high-intensity focused ultrasound treatment, and the nadir-related prediction model might provide a reference for early salvage treatment. Furthermore, Gleason score ≥7, stage ≥T2b might be associated with unfavorable outcomes, although prostate volume and higher initial prostate-specific antigen appear not to be associated with biochemical recurrence for the high-intensity focused ultrasound treatment.
Introduction
Prostate cancer is a commonly diagnosed malignancy in elderly men with rising case numbers. 1 The great proportion of such patients are diagnosed with the status of localized disease. 2 Traditionally, radical prostatectomy, external beam radiotherapy and brachytherapy treatment are the gold standard for localized prostate cancer. However, not all patient cases are suitable for the major operation or can tolerate the toxicity of radiation. The morbidity might have a great influence on the patients' quality of life. Recently, minimally invasive treatments have been developed with acceptable oncological control and limited morbidity.
HIFU was first applied to prostate cancer in 1995, 3 and Uchida et al. reported the first case series of transrectal HIFU for prostate cancer. 4 The mechanism of HIFU is to emit adjustable focused ultrasound energy by a transducer, which causes rapid heat-induced coagulation necrosis and cavitation of targeted cells, but not the intervening structures passed by HIFU. 5, 6 The advantages of HIFU are a minimally invasive nature with lower comorbidity, comparative oncological outcome and repeatability. 7 The European Association of Urology guidelines state that HIFU is an alternative in patients unsuitable for a major operation. 8 However, there is still no consensus about patient selection and prediction of post-HIFU PSA biochemical recurrence, which might reflect biopsy-proven treatment failure or metastatic lesions. For early detection and early salvage treatment, we attempted to find the predictive factors of PSA biochemical recurrence after primary whole-gland HIFU.
Methods
This was a retrospective single-institutional study that enrolled 201 patients from December 2009 to August 2015 with institutional review board approval (103-2399B). All of the patients underwent whole-gland prostate ablation without nerve sparing by intracorporeal HIFU in Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. The diagnosis and staging for all the patients were established by prostate biopsy and magnetic resonance imaging or computed tomography study, and staging was according to the American Joint Committee on Cancer 7th prostate cancer staging system. After excluding patient cases with focal treatment (n = 1), salvage treatment (n = 3), advanced prostate cancer (n = 4) and loss to follow up within 1 year (n = 11), 182 patients were included in our analysis. A total of 24 patients received hormone therapy for 1 month before the operation, and all these patients discontinued the therapy after the surgery. No 5-alpha reductase inhibitor was prescribed for the patients. The patients were treated by Ablatherm integrated imaging (EDAP TMS SA, Vaulx-en-Velin, France). Furthermore, all of the patients underwent radical TURP with as much removal of prostate tissue as possible within the capsule before the operation, and the timing for TURP depended on the prostate size. If the prostate volume before HIFU was <30 mL, a one-stage operation (radical TURP + HIFU) would be carried out. Otherwise, if the volume was ≥30 mL, the HIFU would be carried out 4 weeks after TURP (two stage).
The perioperative parameters were recorded, such as age, preoperative prostate volume, iPSA, Gleason score, status of hormone therapy, the stage of operation, clinical T stage, D'Amico risk group, 9 postoperative PSA nadir, time to PSA nadir, and PSA biochemical recurrence defined by the Phoenix definition (PSA nadir + 2 ng/mL), as for other HIFU studies. 10 Univariate analysis between the two groups is shown in Table 2 . Preoperative prostate volume, iPSA, T stage, Gleason score and PSA nadir all showed a significant difference between the two groups. On multivariate analysis, Cox proportional hazards regression showed Gleason score ≥7 (Gleason score = 3 + 4, HR 4.01, P = 0.011; Gleason score = 4 + 3, HR 6.67, P = 0.001; Gleason score ≥8, HR 4.122, P < 0.001), stage ≥T2b (T2b, HR 3.16, P = 0.027; >T2b, HR 3.77, P = 0.003) and PSA nadir (HR 7.39, P < 0.001) were statistically significant for PSA biochemical recurrence, whereas there was no statistical significance in the pre-HIFU prostate volume (P = 0.353) and iPSA (P = 0.487; Table 3 ).
The ROC analysis of PSA nadir showed the AUC was 0.771 for PSA biochemical recurrence prediction. In addition, we found that PSA nadir cut-off values of 0.43 ng/mL showed 63.3% sensitivity and 79.7% specificity for predicting PSA biochemical recurrence (Table 4 ; Fig. 1 ). Furthermore, if we set PSA nadir values >0.43 ng/mL as a predictor factor, multivariate analysis showed a significant difference of biochemical recurrence (HR 4.02, P < 0.001; Table 3 ). Kaplan-Meier analysis also showed a significant difference for PSA nadir ≥0.43 ng/mL (log-rank test P < 0.001), D'Amico risk (log-rank test low-intermediate P = 0.693, intermediate-high P < 0.001, low-high P = 0.005) (Fig. 2a,  b) . As a result of insufficient prediction efficiency with the D'Amico risk classification, we created a scoring system with better model fit than the D'Amico risk group to predict biochemical recurrence (nadir-prediction model Akaike Information Criterion 402.90, D'Amico classification Akaike Information Criterion 442.69; Table 5 ; Fig. 2c ).
Discussion
To date, postoperative PSA level is an important indicator after definitive treatment of prostate cancer. There is still no consensus of biochemical recurrence in patients receiving HIFU treatment, and we used the Phoenix criteria as our primary outcome, as in other studies. PSA nadir has been proven as the most powerful predictive factor for post-HIFU PSA biochemical recurrence in many studies. [11] [12] [13] [14] In addition, time to PSA nadir in HIFU is much shorter than in radiotherapy (3-6 months vs 18 months). 15, 16 This phenomenon is due to different mechanisms between HIFU (rapid tissue coagulation necrosis and cavitation) and radiotherapy (cell DNA damage with long-term effect). In other words, we can get PSA nadir in HIFU earlier as an indicator for efficacy of HIFU and provide an opportunity for further salvage treatment, such as repetitive HIFU in advance, if required. 17 In addition, the time to biochemical recurrence was rather short for the patients. This might be attributed to a high proportion of high-risk patients newly diagnosed in Taiwan, which is found not only in our institution, but in other studies and all other treatments. 18 In the present study, we considered that PSA nadir level is a gradual continuum correlation with biochemical recurrence, and we elaborated a cut-off level 0.43 ng/mL, which might be considered as an independent predictive factor for PSA biochemical recurrence in HIFU patients in multivariate analysis (P < 0.001, HR 4.02, 95% CI 2.12-7.63). This result echoes previous studies and might help urological oncologists evaluate the outcomes of HIFU earlier, and this cut-off value gives prediction figures of biochemical recurrence of 63.3% sensitivity and 79.3% specificity. Therefore, we created a nadir-related prediction model for biochemical recurrence. The new model has better prediction accuracy than the traditional D'Amico risk classification.
There are conflicting opinions for HIFU among urological societies for prognostic factors of PSA biochemical recurrence: larger preoperative prostate volume 7 with different cut-off values (25 mL 11 and 30 mL, 13 respectively). One study also showed smaller preoperative prostate volume was associated with lower PSA nadir, which indicated favorable oncological outcome. 17 In fact, the treated lesion length for the HIFU machine is limited to 26 mm. If the prostate size is larger, medical (androgen deprivation therapy or 5-alpha reductase inhibitor) or surgical (TURP) volume reduction of the prostate is required before HIFU. 13 There are many advantages of pre-HIFU TURP: prostate volume reduction for better treatment effect, including ventral, apical and intravesical tissue; calcification removal that would attenuate the HIFU energy; prevention of bladder neck contracture; and post-ablative obstruction rate reduction. 19, 20 These advantages of pre-HIFU TURP cannot be overemphasized. Therefore, we routinely carried out extensive TURP to the surgical capsule before HIFU in the present study instead of using 5-alpha reductase inhibitor. The timing of TURP depended on preoperative prostate volume with the cut-off value of 30 mL. However, prostate volume in the biochemical recurrence group was larger than in the biochemical-free group in univariate analysis.
In the present study, preoperative prostate volume and iPSA were not predictive values for successful HIFU treatment in the multivariate analysis. This could be attributed to the iPSA still being affected by the prostate volume, which decreased during radical TURP, and this might affect the results. In addition, we clinically excluded larger prostates for HIFU treatment, and the relatively small prostate volume in the Asian population might also affect these results. We carried out the Pearson correlation coefficient for iPSA and PSA nadir, which showed 0.51 (moderate correlation). It suggested that PSA nadir is related to iPSA, but PSA nadir is a better predictor for biochemical recurrence. Further investigation is warranted to confirm this hypothesis. In addition, no statistical significance for PSA biochemical recurrence between oneor two-stage operation and prostate volume was found, and this might indirectly prove the efficacy of radical TURP before HIFU.
The D'Amico risk group, T stage, Gleason score and iPSA are also prognostic in localized prostate cancer, which is compatible with the present study, whereas previous hormonal therapy showed no difference for the outcome.
9,11 A large retrospective study suggested only Gleason score ≥8, PSA >10 ng/mL, HIFU sessions and PSA nadir were prognostic factors. 11 In previous studies, iPSA 13 with different cut-off values, 11, 14, 21 T stage 11 and Gleason score 11, 12 were independent predictors. Furthermore, many studies excluded the high-risk patient group due to possible unfavorable outcome. 7, 13, 17 Some studies showed that the 5-year PSA biochemical recurrence-free survival rates in D'Amico low-, intermediate-and high-risk patient groups were 84.8-88%, 64.9-83% and 48-54.9%, respectively. Also, 10-year PSA biochemical recurrence-free survival rates in D'Amico low-, intermediate-and high-risk group patients were 71%, 63% and 32%, respectively. Due to the significant statistical difference, they concluded that HIFU was recommended only in D'Amico low-or intermediate-risk group patients. 21, 22 In the present study, the PSA biochemical recurrence-free survival rates in D'Amico low-, intermediate-and high-risk group patients were 91.3%, 88.9% and 58.7%, respectively, at median 32.21 months of follow up. We authentically showed the outcomes of intracorporeal HIFU in the high-risk dominant population in Asia. As for high-risk patients, in comparison with our previous study in cryotherapy, 57.7% biochemical survival rate at a median 34.87-month follow up was found. 23 In other studies, 5-year biochemical recurrencefree survival rate in radical prostatectomy was 55.2%, 24 7-year biochemical recurrence-free survival rate in brachytherapy was 66% (with boost) versus 48% (without boost) in high-risk patients. 25 Although long-term follow-up data are not currently available, the oncological control in HIFU patients seems not significantly inferior to others, but shows better functional outcomes. [26] [27] [28] We suggest that HIFU treatment can still be used in selective high-risk patients.
In conclusion, PSA nadir >0.43 ng/mL and D'Amico highrisk groups, especially with Gleason score ≥7 and clinical stage ≥T2b, were statistically significantly related to biochemical failure after primary whole-gland ablation HIFU. PSA nadir >0.43 provides a better reference value than iPSA for early salvage intervention. For current pre-HIFU candidate selection, the D'Amico risk group seems to be the useful criteria, and for post-HIFU follow up, the nadir-related prediction model might be useful for early salvage treatment. These results provide useful information for urologists in daily practice.
This is the largest retrospective study in an Asian population for investigating risk factors of whole-gland ablation of localized prostate cancer with Ablatherm-integrated imaging HIFU. Compared with other reports, we had a large proportion of high-risk patients and the results were compatible. Furthermore, we elaborate a cut-off level, which might be considered as an independent predictive factor for PSA biochemical recurrence after HIFU, and a nadir-related prediction model, which might be useful for salvage treatment.
Nevertheless, there were limitations to the study. It was a single institutional retrospective study with a relatively shorter follow-up period (median 32.35 AE 15.47 months), whereas Sung et al. reported that the median time to PSA biochemical recurrence after HIFU was 13.8 months during a median follow-up period of 5.1 years. 29 Thus, the follow-up period might be sufficient for early evaluation of biochemical recurrence. In addition, there are no further comparisons between HIFU with or without TURP, so this issue should still be discussed in future investigations. Furthermore, our aim in the present study was to create the best model including the nadir. However, the power and external validity of the model might be limited due to our limited case number, and we will focus on creating a better model for HIFU therapy in the future. Finally, we did not carry out prostate biopsy for all the post-HIFU patients, so the correlation between biochemical recurrence and true biopsy-proven recurrence was limited.
